Liquidia Technologies is projected to report Q2 2026 revenue of $168.48 million and EPS of $0.76, while its current stock price of $90.22 sits slightly above the average analyst target of $85.67.
Investors are primarily focused on the commercial trajectory of YUTREPIA, the company's dry-powder inhaled treprostinil for PAH and PH-ILD.
Following its June 2025 launch, YUTREPIA has seen rapid adoption, reaching approximately $130 million in sales during the first quarter of 2026. Management's ability to maintain this momentum and expand the prescriber base will be critical as the company targets a $1 billion annual revenue run rate by 2027.